NO20000265L - Kontrollerte cytolyser av mõlceller, midler og sammensetninger som forõrsaker cytolyse og forbindelser som kan anvendes for õ fremstille midlene - Google Patents

Kontrollerte cytolyser av mõlceller, midler og sammensetninger som forõrsaker cytolyse og forbindelser som kan anvendes for õ fremstille midlene

Info

Publication number
NO20000265L
NO20000265L NO20000265A NO20000265A NO20000265L NO 20000265 L NO20000265 L NO 20000265L NO 20000265 A NO20000265 A NO 20000265A NO 20000265 A NO20000265 A NO 20000265A NO 20000265 L NO20000265 L NO 20000265L
Authority
NO
Norway
Prior art keywords
agents
cytolysis
prepare
compositions
compounds
Prior art date
Application number
NO20000265A
Other languages
English (en)
Other versions
NO20000265D0 (no
Inventor
Morten Soegaard
Lars Abrahamsen
Peter Lando
Goeran Forsberg
Terje Kalland
Mikael Dohlsten
Original Assignee
Pharmacia & Upjohn Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE9704170A external-priority patent/SE9704170D0/xx
Application filed by Pharmacia & Upjohn Ab filed Critical Pharmacia & Upjohn Ab
Publication of NO20000265D0 publication Critical patent/NO20000265D0/no
Publication of NO20000265L publication Critical patent/NO20000265L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6829—Bacterial toxins, e.g. diphteria toxins or Pseudomonas exotoxin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6863—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from stomach or intestines cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
NO20000265A 1997-07-21 2000-01-19 Kontrollerte cytolyser av mõlceller, midler og sammensetninger som forõrsaker cytolyse og forbindelser som kan anvendes for õ fremstille midlene NO20000265L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5321197P 1997-07-21 1997-07-21
SE9704170A SE9704170D0 (sv) 1997-11-14 1997-11-14 Directed cytolysis of target cells, agents and compositions causing cytolysis, and compounds that can be used to produce the agents
PCT/EP1998/004219 WO1999004820A2 (en) 1997-07-21 1998-07-02 Cytolysis of target cells by superantigen conjugates inducing t-cell activation

Publications (2)

Publication Number Publication Date
NO20000265D0 NO20000265D0 (no) 2000-01-19
NO20000265L true NO20000265L (no) 2000-03-15

Family

ID=26663128

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20000265A NO20000265L (no) 1997-07-21 2000-01-19 Kontrollerte cytolyser av mõlceller, midler og sammensetninger som forõrsaker cytolyse og forbindelser som kan anvendes for õ fremstille midlene

Country Status (19)

Country Link
US (2) US6962694B1 (no)
EP (1) EP0998305B1 (no)
JP (1) JP2001510687A (no)
KR (1) KR20010022075A (no)
CN (1) CN1275085A (no)
AR (1) AR013230A1 (no)
AT (1) ATE361102T1 (no)
AU (1) AU748097B2 (no)
BR (1) BR9815493A (no)
CA (1) CA2296798A1 (no)
DE (1) DE69837706T2 (no)
EA (1) EA002688B1 (no)
ES (1) ES2284209T3 (no)
ID (1) ID24097A (no)
IL (1) IL133883A0 (no)
NO (1) NO20000265L (no)
NZ (1) NZ502745A (no)
PL (1) PL338338A1 (no)
WO (1) WO1999004820A2 (no)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010023288A1 (en) 1999-07-07 2001-09-20 Wilbur D. Scott Trifunctional reagent for conjugation to a biomolecule
WO2000002050A1 (en) * 1998-07-07 2000-01-13 Department Of Radiation Oncology, University Of Washington Trifunctional reagent for conjugation to a biomolecule
SE0102327D0 (sv) * 2001-06-28 2001-06-28 Active Biotech Ab A novel engineered superantigen for human therapy
SE0402025D0 (sv) * 2004-08-13 2004-08-13 Active Biotech Ab Treatment of hyperproliferative disease with superantigens in combination with another anticancer agent
US7885841B2 (en) * 2006-01-05 2011-02-08 Oracle International Corporation Audit planning
DE102007004855B4 (de) * 2007-01-31 2014-03-27 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Vorrichtung und Verfahren zur Deposition von biologischem Material in einem Zielsubstrat
EP2134373A4 (en) 2007-02-28 2014-04-02 Yeda Res & Dev CORE TARGETING SEQUENCES
EP2600901B1 (en) 2010-08-06 2019-03-27 ModernaTX, Inc. A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
CN104531671A (zh) 2010-10-01 2015-04-22 现代治疗公司 设计核酸及其使用方法
CA2831613A1 (en) 2011-03-31 2012-10-04 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
EP2723380B1 (en) * 2011-06-24 2019-08-21 Stephen D. Gillies Light chain immunoglobulin fusion proteins and methods of use thereof
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP3682905B1 (en) 2011-10-03 2021-12-01 ModernaTX, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
ES2923757T3 (es) 2011-12-16 2022-09-30 Modernatx Inc Composiciones de ARNm modificado
US9303079B2 (en) 2012-04-02 2016-04-05 Moderna Therapeutics, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
AU2013243953A1 (en) 2012-04-02 2014-10-30 Modernatx, Inc. Modified polynucleotides for the production of nuclear proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
DK2922554T3 (en) 2012-11-26 2022-05-23 Modernatx Inc Terminalt modificeret rna
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
WO2015040609A1 (en) 2013-09-17 2015-03-26 Yeda Research And Development Co. Ltd. Erk-derived peptides and uses thereof
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
WO2015051214A1 (en) 2013-10-03 2015-04-09 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
US10314910B2 (en) 2016-01-10 2019-06-11 Neotx Therapeutics Ltd. Methods and compositions for enhancing the potency of superantigen mediated cancer immunotherapy
WO2018067461A1 (en) * 2016-10-05 2018-04-12 The Regents Of The University Of California Viral disk assemblies and methods of use thereof
US11845797B2 (en) * 2018-07-03 2023-12-19 Marengo Therapeutics, Inc. Anti-TCR antibody molecules and uses thereof
KR20220009428A (ko) 2019-05-15 2022-01-24 네오티엑스 테라퓨틱스 엘티디. 암 치료
CN115484978A (zh) 2020-03-05 2022-12-16 尼奥克斯医疗有限公司 使用免疫细胞治疗癌症的方法和组合物

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993024136A1 (en) * 1991-01-17 1993-12-09 Terman David S Tumor killing effects of enterotoxins, superantigens, and related compounds
US5545716A (en) * 1992-09-08 1996-08-13 University Of Florida Superantigen agonist and antagonist peptides
US5635599A (en) * 1994-04-08 1997-06-03 The United States Of America As Represented By The Department Of Health And Human Services Fusion proteins comprising circularly permuted ligands
IL113484A0 (en) * 1994-04-28 1995-07-31 Immunex Corp Viral proteins pharmaceutical compositions containing them their preparation and use
SE9402430L (sv) * 1994-07-11 1996-01-12 Pharmacia Ab Konjugat mellan modifierat superantigen och en målsökande förening samt användning av konjugaten
US5541087A (en) * 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
US5716623A (en) * 1994-12-07 1998-02-10 Immunex Corporation Isolated Herpesvirus saimiri proteins that bind MHC Class II molecules
US5935568A (en) * 1995-05-18 1999-08-10 National Jewish Medical & Research Center Gene therapy for effector cell regulation
US5705151A (en) * 1995-05-18 1998-01-06 National Jewish Center For Immunology & Respiratory Medicine Gene therapy for T cell regulation
SE9601245D0 (sv) * 1996-03-29 1996-03-29 Pharmacia Ab Chimeric superantigens and their use
TW517061B (en) * 1996-03-29 2003-01-11 Pharmacia & Amp Upjohn Ab Modified/chimeric superantigens and their use
WO1998026747A2 (en) * 1996-12-17 1998-06-25 Terman David S Superantigen based methods and compositions for treatment of diseases
US6075119A (en) * 1997-04-07 2000-06-13 The Rockefeller University Peptides useful for reducing symptoms of toxic shock syndrome
SE0102327D0 (sv) * 2001-06-28 2001-06-28 Active Biotech Ab A novel engineered superantigen for human therapy

Also Published As

Publication number Publication date
ES2284209T3 (es) 2007-11-01
WO1999004820A2 (en) 1999-02-04
ID24097A (id) 2000-07-06
JP2001510687A (ja) 2001-08-07
AU748097B2 (en) 2002-05-30
DE69837706D1 (de) 2007-06-14
EA200000144A1 (ru) 2000-08-28
US20050226885A1 (en) 2005-10-13
BR9815493A (pt) 2000-10-31
DE69837706T2 (de) 2008-01-10
EP0998305B1 (en) 2007-05-02
PL338338A1 (en) 2000-10-23
AR013230A1 (es) 2000-12-13
EP0998305A2 (en) 2000-05-10
NZ502745A (en) 2003-02-28
EA002688B1 (ru) 2002-08-29
KR20010022075A (ko) 2001-03-15
CN1275085A (zh) 2000-11-29
NO20000265D0 (no) 2000-01-19
AU8441598A (en) 1999-02-16
US6962694B1 (en) 2005-11-08
IL133883A0 (en) 2001-04-30
ATE361102T1 (de) 2007-05-15
WO1999004820A3 (en) 1999-08-12
CA2296798A1 (en) 1999-02-04

Similar Documents

Publication Publication Date Title
NO20000265L (no) Kontrollerte cytolyser av mõlceller, midler og sammensetninger som forõrsaker cytolyse og forbindelser som kan anvendes for õ fremstille midlene
NO871361D0 (no) Fremgangsmaate for redusering av fluidtap i sementsammensetninger som kan inneholde vesentlige saltkonsentrasjoner.
DK2412368T3 (da) Sammensætning til behandling af ar
ID23807A (id) Metoda dan komposisi yang mengandung-semen untuk digunakan dalam bawah tanah
ID16493A (id) Perlakuan bahan yang mengandung padatan yang diambil dari efluen
ATE232556T1 (de) Brausezusammensetzungen sowie trockene brausegranulate
EE03741B1 (et) N-propargüül-1-aminoindaani R-enantiomeeri, sellesoolade ja kompositsioonide kasutamine
DK1038008T3 (da) Fremgangsmåde til fremstilling af EGIII-lignende enzymer
DK159146C (da) Analogifremgangsmaade til fremstilling af 1,2-diaminocyclobuten-3,4-dioner og cyclobuten-3,4-dionderivater til anvendelse som mellemprodukter i fremgangsmaaden
NO983766D0 (no) FremgangsmÕte til fremstilling av N-acetyl-D-glukosamin
MX15701A (es) Composiciones de macrolidas y procedimiento para su preparacion.
DK0760238T3 (da) Præparat, der kan indgives perkutant, til behandling af vandladningslidelse
ID28471A (id) Komposisi-komposisi binatu yang mengandung bahan-bahan pendispersi polialkilenaimina teralkoksilasi
NO984761D0 (no) Aminoisokinoliner og aminotienopyridinderivater og deres anvendelse som antiinflammatoriske midler
BR9706908A (pt) Composiçães para o tratamento de insuficiéncia renal compreendendo l-carnosina
NO993067L (no) Farmasoeytiske sammensetninger for frysetoerking
NO960272D0 (no) Oksatiolaner, fremgangsmåte for deres fremstilling og farmasöytiske preparater som inneholder de samme
NO981818D0 (no) FremgangsmÕte for Õ mobilisere hematopoetiske stamceller
PT853959E (pt) Composicao para o tratamento do amianto
BR9806083A (pt) Composi-Æo farmac-utica para o tratamento da hapattite c
DK158990C (da) Cholestadienderivat, der kan anvendes som mellemprodukt til brug ved fremstillingen af homovitamin-d3-derivater
DK2281892T3 (da) Fremgangsmåde til fremstilling af respiratorisk-deficiente Trichoderma-celler
FI972058A0 (fi) Foerfarande foer reglering av en saendares effekt och regleringsarrangemang
ID17941A (id) Metode penerapan komposisi pembuat marka jalan
MX9102625A (es) Composiciones de electrorrevestimiento catodico y metodo para su preparacion.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application